A Rare Disease Getting Rarer Attention
So here's a condition that most people have never heard of, but for roughly 50,000 South Koreans β and about 6,000 in the most severe category β it is a daily, life-threatening reality. Pulmonary arterial hypertension, or PAH, is a rare and serious disease that causes dangerously high blood pressure in the arteries that connect the heart to the lungs. Left untreated or under-treated, it can be fatal within years of diagnosis.
The good news is that South Korea is making real progress. The bad news? It's still not enough β and a major medical conference held this week in Seoul is pushing hard to change that.
What Happened at PH Korea 2026
On June 26, the Korean Society for Pulmonary Hypertension β known in Korean as λννκ³ νμνν, or KSPH β held its 11th annual academic conference at COEX in Seoul's Magok district. The event, called PH Korea 2026, brought together specialists from South Korea and around the world to tackle some stubborn problems: slow drug approvals, outdated disease classification systems, and a lack of a uniquely Korean clinical guideline.
What's really interesting is that this year's conference wasn't just about academic papers. It was notably policy-forward β a room full of cardiologists and pulmonologists essentially telling the government: here's what needs to change, and here's why it matters for patients right now.
The Numbers Behind the Problem
Let's put the scale of this in perspective. Pulmonary hypertension β in all its forms β affects about 1% of the global population. In South Korea, that translates to an estimated 500,000 people. The most critical subset, those classified under WHO Group 1 (pulmonary arterial hypertension), numbers around 6,000 patients in the country.
For those patients, the five-year survival rate currently sits at approximately 71.8%. That sounds reasonable on the surface, but medical professionals are quick to note that it remains below the benchmarks set by more advanced healthcare systems in Europe and North America. And given that PAH often goes undiagnosed for years due to its vague early symptoms β think fatigue, breathlessness, things easily mistaken for other conditions β many patients are already in serious condition by the time they get the right diagnosis.
The Drug Access Gap
Here's where things get frustrating. Several breakthrough treatments already exist and have proven themselves in clinical settings abroad. Two that were specifically highlighted at the conference are Winrevair (sotatercept) and Veletri (epoprostenol) β both targeted therapies that have shown meaningful results in extending and improving patients' lives.
The problem is that getting these drugs approved, listed under South Korea's national health insurance, and actually available to patients is a slow and complicated process. For a rare disease where time is genuinely of the essence, delays in insurance coverage can be the difference between a patient getting better treatment or not.
Kim Kye-hoon, the incoming president of the KSPH and a professor at Chonnam National University Medical School, made the case directly at the conference: the regulatory and insurance listing processes need to move faster for drugs that have already cleared international safety and efficacy standards.
"Despite the positive trajectory of pulmonary hypertension treatment outcomes in Korea, patient access to new drugs and policy support still leave much to be desired," said KSPH President Jung Wook-jin, a professor at Gachon University College of Medicine. "To genuinely improve survival rates and quality of life, we need a closely coordinated system between medical professionals, the government, and patients."
Korea's First-Ever Domestic Clinical Guidelines
One of the most significant announcements to come out of PH Korea 2026 was the impending release of South Korea's first-ever official domestic clinical guidelines for pulmonary hypertension. This is actually a bigger deal than it might sound.
Up until now, Korean doctors have largely relied on international guidelines β primarily from Europe and the United States β that weren't necessarily designed with Korean patients and the Korean healthcare environment in mind. Rare diseases are notoriously difficult to study because the patient populations are small, making it hard to build the kind of large-scale data that typically drives guideline creation.
Kim Kyung-hee, chair of the KSPH's guideline development committee and a specialist at Incheon Sejong Hospital, explained the thinking behind the Korean-specific approach: rather than simply adapting foreign guidelines, the goal was to build something grounded in Korea's own diagnostic and treatment ecosystem.
The new guidelines are expected to be formally unveiled in Korean at the Korean Society of Cardiology conference in November this year, with an English-language version to follow in January 2026. Importantly, the society hopes these guidelines will serve as a concrete evidence base for reforming Korea's national health insurance reimbursement criteria β which currently lags behind international standards in several areas related to PAH treatment.
Fixing the Classification System
Another policy push from the conference addressed something more technical but equally important: how pulmonary hypertension is classified in Korea's official disease coding system, the KCD (Korean Standard Classification of Diseases).
Kim Dae-hee, the society's administrative director and a professor at Ulsan University College of Medicine, pointed out that the current classification system doesn't fully reflect the clinical complexity and burden of pulmonary hypertension. Better classification isn't just bureaucratic housekeeping β it directly impacts how the government tracks patients, allocates resources, and designs care pathways.
Long-Term Research and Regional Ambitions
Beyond the immediate policy pushes, the KSPH is investing in the long game. The society has been running a precision medicine cohort study called PHOENIKS in partnership with the Korea Disease Control and Prevention Agency's National Institute of Health β and this year marks the ninth consecutive year of that collaboration. The plan is to keep expanding it, building the kind of long-term, high-quality data that can eventually drive better care for future patients.
And on the international front, the KSPH is thinking big. In June of next year, to mark the society's 10th anniversary, it will co-host the East Asian Society of Pulmonary Hypertension (EASOPH) academic conference β again at COEX Magok in Seoul. It's a signal that South Korea wants to position itself not just as a fast-follower in PAH care, but as a regional leader shaping the conversation across Asia.
What This Means for Patients
So here's the thing about rare diseases β they rarely get the kind of public attention that drives policy change quickly. PAH is not a household name, and its patients are a relatively small (though deeply affected) group. That's exactly why conferences like PH Korea 2026 matter: they create a formal, documented record of what the medical community is calling for, and they give advocates a platform to apply sustained pressure on policymakers.
For the roughly 6,000 South Koreans living with pulmonary arterial hypertension, the asks on the table are clear β faster drug approvals, expanded insurance coverage, a Korean-tailored clinical framework, and smarter disease tracking. None of these are unreasonable. What remains to be seen is whether the policy machinery moves fast enough to make a real difference for patients who are, quite literally, running out of time.
This article is based on reports from Dong-A Ilbo, Bosa, Newstown.